1067 Analysis of the EORTC Melanoma Group 18952 randomized trial on 2 intermediate dose schedules of IFN-alpha2b compared with observation in 1388 patients with high risk melanoma stages IIB-III

✍ Scribed by Eggermont, A.M.M.; Suciu, S.; Ruka, W.; Testori, A.; Kruit, W.; Punt, C.J.A.; Delaunay, M.; Sales, F.; Stoitchkov, K.; Groenewegen, G.; Mackie, R.; Patel, P.; Lienard, D.

• Book ID: 123197191
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 150 KB
• Volume: 1
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(03)91093-7